Progressively Tumorigenic Cell Lines for Metastatic Cancer Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current models for studying cancer progression lack the ability to evaluate the anti-neoplastic potential of therapeutic agents against a series of increasingly aggressive tumors derived from a single progenitor cell type, failing to accurately recapitulate the in vivo transitions of human cancers from localized to metastatic states.
Innovation Solution
Development of tumorigenic cell lines (T1-A, T2-A, T3-PA, T3-HA, and T4-PA) derived from a common HRAS-transfected progenitor cell line, which, when injected into non-human animals, produce a series of tumors ranging from primary to metastatic, allowing for the evaluation of anti-neoplastic agents across different stages of tumorigenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If primary embryonic cells or cell lines are used as models to evaluate therapeutic effects, then the model system is simple and easy to operate, but the model fails to accurately recapitulate in vivo transitions of human cancers from localized to metastatic states
Solution Approach 1:
The patent segments the continuous tumorigenic progression process into distinct sequential stages (T1, T2, T3, T4) with increasing metastatic potential. Each stage represents a discrete step in cancer progression from localized to highly metastatic states, allowing researchers to evaluate therapeutic agents at specific progression points while maintaining in vivo relevance through sequential in vivo passage of cells between stages.
2Adaptability or versatility
If a model system uses tumors from different progenitor cell types, then the model can evaluate diverse cancer types, but the model fails to provide sequential evaluation against increasingly aggressive tumors from a single progenitor
Solution Approach 1:
The patent creates a universal progenitor cell line (NIH/3T3) that can generate multiple tumor stages (T1-T4) with progressively increasing metastatic potential. This single progenitor system serves multiple functions: evaluating therapeutic agents against increasing aggression, studying metastatic progression mechanisms, and providing a standardized model that eliminates variability between different cell types while maintaining adaptability to test various therapeutic interventions.
Data Source
AI summary
Provided herein, inter alia, are tumorigenic cell lines and methods for using the same for deriving a series of cell culture and non-human animal-based models which exhibit increasingly aggressive tumorigenic potential as well as use of the same for evaluating the anti-neoplastic properties of candidate therapeutic agents.